Hostname: page-component-7b7567c8c-48dgx Total loading time: 0 Render date: 2026-11-18T03:15:08.202Z Has data issue: false hasContentIssue false

Stakeholder perspectives on cooperation in the clinical and nonclinical health technology assessment domains

Published online by Cambridge University Press:  22 May 2023

Gina Zimmermann
Affiliation:
Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands
Sandra Michelmore
Affiliation:
UCB Pharma Ltd., Slough, UK
Mickaël Hiligsmann*
Affiliation:
Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands
*
Corresponding author: Mickaël Hiligsmann; Email: m.hiligsmann@maastrichtuniversity.nl
Rights & Permissions [Opens in a new window]

Abstract

Objectives

The aim of this study was to deliver insights from multiple stakeholders into actual and future collaboration for health technology assessment (HTA) in general and in oncology in particular.

Methods

Eighteen semi-structured interviews were conducted with experts from European HTA bodies (HTAbs), former board members of the European Network for Health Technology Assessment (EUnetHTA), and representatives from the pharmaceutical industry, a regulatory agency, academia, and patient organizations. The stakeholders were asked about their support of the EUnetHTA’s intent, about the general strengths and challenges of the EUnetHTA and its Joint Action 3 (JA 3), the strengths and challenges of the clinically oriented HTA collaboration in oncology during JA 3 across the technology life cycle, about future challenges to HTA in oncology with consequences for collaboration, and about collaboration in the economic domains of HTA. The transcribed interviews were analyzed qualitatively.

Results

The participants perceived the intention and work quality of the EUnetHTA as positive. The experts described methodological, procedural, and capacity challenges in early dialogues (EDs) and rapid relative effectiveness assessments (REAs) meant to analyze clinical effectiveness in oncology. The majority attached increasing importance to collaboration in the future to cope with the uncertainty of HTA. Several stakeholders also proposed the incorporation of joint postlaunch evidence generation (PLEG) activities. Some gave sporadic suggestions for voluntary nonclinical collaboration as well.

Conclusion

Stakeholders’ continued readiness to discuss the remaining challenges to and sufficient resources for implementing HTA regulation, as well as further cooperative expansion along the technology life cycle, are necessary for improved HTA collaboration in Europe.

Information

Type
Policy
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press
Figure 0

Table 1.Interview questions

Figure 1

Table 2.Full interview findings